PG
BIO icon

Pendal Group’s Bio-Rad Laboratories Class A BIO Stock Holding History

Pendal Group’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,096
Closed -$617K – 461
2022
Q1 		$617K Buy
+1,096
New +$661K 0.01% 383
2020
Q4 		– Sell
-526
Closed -$271K – 512
2020
Q3 		$271K Sell
526
-1,147
-69% -$581K ﹤0.01% 371
2020
Q2 		$755K Buy
1,673
+1,062
+174% +$469K 0.01% 268
2020
Q1 		$214K Buy
611
+372
+156% +$137K ﹤0.01% 333
2019
Q4 		$88.4K Buy
+239
New +$84.3K ﹤0.01% 398

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Pendal Group's BIO Position: Q2 2022 in Review

Pendal Group sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2022, closing a stake of 1,096 shares — an estimated $617K sold.

Pendal Group first reported a position in BIO in Q4 2019 and held it in 5 quarters. The position peaked at $755K in Q2 2020. 500 funds tracked by Wall St. Rank hold BIO as of Q2 2022.

  • Pendal Group reported no remaining Bio-Rad Laboratories Class A position as of Q2 2022 after selling out during the quarter.
  • Pendal Group sold 1,096 Bio-Rad Laboratories Class A shares in Q2 2022, an estimated $617K.
  • Pendal Group first reported a position in Bio-Rad Laboratories Class A in Q4 2019 and held it in 5 quarters.
  • Pendal Group's Bio-Rad Laboratories Class A position peaked at $755K in Q2 2020.
  • 500 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2022.

Based on Pendal Group's 13F filing for Q2 2022, filed 25 Jul 2022.